lomustine and toceranib phosphate

lomustine has been researched along with toceranib phosphate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Al-Sarraf, R; Johnson, CS; Malone, EK; Rassnick, KM; Ruslander, DM; Russell, DS; Trump, DL; Wakshlag, JJ	1
Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM	1
Argyle, DJ; Bavcar, S; Buracco, P; de Fornel, P; de Vos, J; Hirschberger, J; Kessler, M; Murphy, S	1

Trials

2 trial(s) available for lomustine and toceranib phosphate

Article	Year
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and comparative oncology, 2010, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine	2010
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study. Veterinary and comparative oncology, 2016, Volume: 14, Issue:2 Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Indoles; Lomustine; Neoplasms; Pyrroles	2016

Article

Year

Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.

Veterinary and comparative oncology, 2010, Volume: 8, Issue:3

Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine

2010

Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.

Veterinary and comparative oncology, 2016, Volume: 14, Issue:2

Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Indoles; Lomustine; Neoplasms; Pyrroles

2016

Other Studies

1 other study(ies) available for lomustine and toceranib phosphate

Article	Year
Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. Veterinary journal (London, England : 1997), 2017, Volume: 224 Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Europe; Indoles; Lomustine; Mast Cells; Neoplasm Recurrence, Local; Prednisolone; Prospective Studies; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms	2017

Article

Year

Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.

Veterinary journal (London, England : 1997), 2017, Volume: 224

Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Europe; Indoles; Lomustine; Mast Cells; Neoplasm Recurrence, Local; Prednisolone; Prospective Studies; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms

2017